The new version of the BIOSECURE Act moving through the House gives industry more time than the original draft to transition away from Chinese biotech suppliers, but it may not give all of them enough.
And given that
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?